Ravulizumab (indication: neuromyelitis optica spectrum disorder (NMOSD), anti-aquaporin-4 (AQP4) IgG-sero-positive)



  • Active Substance: Ravulizumab
  • Name: Ultomiris®
  • Therapeutic area: Neuromyelitis optica spectrum disorder (NMOSD)
  • Pharmaceutical company: Alexion Pharma Germany GmbH


Time table:

  • Start: 15.06.2023
  • Publication of assessment: 15.09.2023
  • End of public hearing: 06.10.2023
  • Final decision by G-BA: beginning of December 2023


Comparative therapy:

  • Eculizumab (from the 2nd disease episode onwards) or satralizumab)